H.C. Wainwright raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $21 from $8 and keeps a Buy rating on the shares. The firm believes the valuation argument for Neuphoria “is a compelling one” as the BNC210 “evolution pushes forward.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.